Recombinant adeno-associated virus vectors for somatic gene therapy in dermatology

Expert Review of Dermatology

Volumn 2, Issue 2, 2007, Pages 167-177

  Braun Falco, Markus ^a   Rödl, Daniela ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

adeno associated virus; cutaneous gene therapy; gene therapy; genodermatoses; skin gene therapy; wound healing

Indexed keywords

EID: 79951577461     PISSN: 17469872     EISSN: 17469880     Source Type: Journal    
DOI: 10.1586/17469872.2.2.167     Document Type: Article

References (90)

1. Khavari PA, Rollman O, Vahlquist A. Cutaneous gene transfer for skin and systemic diseases. J. Intern. Med. 252 (1), 1–10 (2002).
2. Flotte TR, Berns KI (Ed.). Adeno-associated Virus Vectors for Gene Therapy (1st Edition). Elsevier Science Ltd, GA, USA (2005).
3. Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 14 (3), 316–327 (2006).
4. Gao G, Vandenberghe LH, Wilson JM. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5 (3), 285–297 (2005).
5. Gao G, Vandenberghe LH, Alvira MR et al. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78 (12), 6381–6388 (2004).
6. Wu Z, Asokan A, Grieger JC et al. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. J. Virol. 80 (22), 11393–11397 (2006).
7. Mori S, Wang L, Takeuchi T, Kanda T. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology 330 (2), 375–383 (2004).
8. Chiorini JA, Wiener SM, Yang L et al. The roles of AAV Rep proteins in gene expression and targeted integration. Curr. Top. Microbiol. Immunol. 218, 25–33 (1996).
9. Muzyczka N, Warrington KH Jr. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum. Gene Ther. 16 (4), 408–416 (2005).
10. Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of adeno-associated viral vectors. Gene Ther. 12 (11), 873–880 (2005).
11. Sanlioglu S, Monick MM, Luleci G, Hunninghake GW, Engelhardt JF. Rate limiting steps of AAV transduction and implications for human gene therapy. Curr. Gene Ther. 1 (2), 137–147 (2001).
12. Bartlett JS, Wilcher R, Samulski RJ. Infectious pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74 (6), 2777–2785 (2000).
13. Douar AM, Poulard K, Stockholm D, Danos O. Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol. 75 (4), 1824–1833 (2001).
14. Zhao W, Zhong L, Wu J et al. Role of cellular FKBP52 protein in intracellular trafficking of recombinant adeno-associated virus 2 vectors. Virology 353 (2), 283–293 (2006).
15. Nakai H, Storm TA, Kay MA. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J. Virol. 74 (20), 9451–9463 (2000).
16. Samulski Rj, Berns KI, Tan M, Muzyczka N. Cloning of infectious adeno-associated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc. Natl Acad. Sci. USA 79 (6), 2077–2081 (1982).
17. Carter BJ. Adeno-associated virus and the development of adeno-associated virus vectors: a historical perspective. Mol. Ther. 10 (6), 981–989 (2004).
18. Grimm D, Kay MA. From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3 (4), 281–304 (2003).
19. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72 (3), 2224–2232 (1998).
20. Merten O-W, Gény-Fiamma C, Douar AM. Current issues in adeno-associated viral vector production. Gene Ther. 12 (Suppl. 1), S51 –S61 (2005).
21. Zolotukhin S. Production of recombinant adeno-associated virus vectors. Hum. Gene Ther. 16 (5), 551–557 (2005).
22. Le Bec C, Douar AM. Gene therapy progress and prospects – vectorology: design and production of expression cassettes in AAV vectors. Gene Ther. 13 (10), 805–813 (2006).
23. Zolotukhin S, Byrne BJ, Mason E et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6 (6), 973–985 (1999).
24. Arnold GS, Sasser AK, Stachler MD, Bartlett JS. Metabolic biotinylation provides a unique platform for the purification and targeting of multiple AAV vector serotypes. Mol. Ther. 14 (1), 97–106 (2006).
25. Zhang HG, Xie J, Dmitriev I et al. Addition of six-His-tagged peptide to the C terminus of adeno-associated virus VP3 does not affect viral tropism or production. J. Virol. 76 (23), 12023–12031 (2002).
26. During MJ, Samulski RJ, Elsworth JD et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther. 5 (6), 820–827 (1998).
27. Herzog RW. AAV-mediated gene transfer to skeletal muscle. Methods Mol. Biol. 246, 179–194 (2004).
28. Snyder RO, Miao CH, Meuse L et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5 (1), 64–70 (1999).
29. Zhong L, Zhao W, Wu J, Maina N, Han Z, Srivastava A. Adeno-associated virus-mediated gene transfer in hematopoietic stem/progenitor cells as a therapeutic tool. Curr. Gene Ther. 6 (6), 683–698 (2006).
30. Pacak CA, Mah CS, Thattaliyath BD et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99 (4), e3 –e9 (2006).
31. Burger C, Gorbatyuk OS, Velardo MJ et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10 (2), 302–317 (2004).
32. Davidson BL, Stein CS, Heth JA et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl Acad. Sci. USA 97 (7), 3428–3432 (2000).
33. Nakai H, Fues S, Storm S, Muramatsu S, Nara Y, Kay MA. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J. Virol. 79 (1), 214–224 (2005).
34. Wang Z, Zhu T, Qiao C et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23 (3), 321–328 (2005).
35. Gregorevic P, Blankinship MJ, Allen JM et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10 (8), 828–834 (2004).
36. Grimm D, Pandey K, Nakai H, Storm TA, Kay MA. Liver transduction with recombinant adeno-associated virus is primarily restricted by capsid serotype not vector genotype. J. Virol. 80 (1), 426–439 (2006).
37. Gao GP, Alvira MR, Wang L et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl Acad. Sci. USA 99 (18), 11854–11859 (2002).
38. Blankinship MJ, Gregorevic P, Allen JM et al. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol. Ther. 10 (4), 671–678 (2004).
39. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol. Ther. 2 (6), 619–623 (2000).
40. McCarty DM, Young SM Jr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu. Rev. Genet. 38, 819–845 (2004).
41. Huser D, Weger S, Heilbronn R. Kinetics and frequency of adeno-associated virus site-specific integration into human chromosome 19 monitored by quantitative real-time PCR. J. Virol. 76 (15), 7554–7559 (2002).
42. Nakai H, Montini E, Fuess S et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat. Genet. 34 (3), 297–302 (2003).
43. Nakai H, Wu X, Fuess S et al. Large-scale molecular characterization of adeno-associated virus vector integration in mouse liver. J. Virol. 79 (6), 3606–3614 (2005).
44. Nakai H, Yant SR, Storm T et al. Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75 (15), 6969–6976 (2001).
45. Schnepp BC, Clark KR, Klemanski DL et al. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J. Virol. 77 (6), 3495–3504 (2003).
46. Flotte TR, Zeitlin PL, Reynolds TC et al. Phase I trial of of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum. Gene Ther. 14 (11), 1079–1088 (2003).
47. Carter BJ. Adeno-associated virus vectors in clinical trials. Hum. Gene Ther. 16 (5), 541–550 (2005).
48. Warrington KH Jr, Herzog RW. Treatment of human disease by adeno-associated viral gene transfer. Hum. Genet. 119 (6), 571–603 (2006).
49. Moss RB, Rodman D, Spencer LT et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multi-center, double-blind, placebo-controlled trial. Chest 125 (2), 509–521 (2004).
50. Manno CS, Chew AJ, Hutchison S et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101 (8), 2963–2972 (2003).
51. Jiang H, Pierce GF, Ozelo MC et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol. Ther. 14 (3), 452–455 (2006).
52. Manno CS, Pierce GF, Arruda VR et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 12 (3), 342–347 (2006).
53. Boyce N. Trial halted after gene shows up in semen. Nature 414 (6865), 677 (2001).
54. Ghazizadeh S, Taichman LB. Virus-mediated gene transfer for cutaneous gene therapy. Gene Ther. 11 (16), 2247–2251 (2000).
55. Meyers C, Mane M, Kokorina N et al. Ubiquitous human adeno-associated virus type 2 autonomously replicates in differentiating keratinocytes of a normal skin model. Virology 272 (2), 338–346 (2000).
56. Hermonat PL, Plott RT, Santin AD et al. Adeno-associated virus Rep 78 inhibitis oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric. Gynecol. Oncol. 66 (3), 487–494 (1997).
57. Braun-Falco M, Doenecke A, Smola H, Hallek M. Efficient gene transfer into human keratinocytes with recombinant adeno-associated virus vectors. Gene Ther. 6 (3), 432–441 (1999).
58. Braun-Falco M, Eisenried A, Büning H, Ring J. Recombinant adeno-associated virus-mediated gene transfer into human keratinocytes is influenced by both ubiquitin/proteasome pathway and epidermal growth factor-receptor tyrosine kinase. Arch. Dermatol. Res. 296 (11), 528–535 (2005).
59. Büning H, Braun-Falco M, Hallek M. Progress in the use of adeno-associated virus vectors for gene therapy. Cells Tiss. Org. 177 (3), 139–150 (2004).
60. Agrawal N, You H, Liu Y et al. Generation of recombinant skin in vitro by adeno-associated virus type 2 vector transduction. Tiss. Eng. 10 (11/12), 1707–1715 (2004).
61. Recchia A, Perani L, Sartori D et al. Site-specific integration of functional transgenes into the human genome by adeno/AAV hybrid vectors. Mol. Ther. 10 (4), 660–669 (2004).
62. Hengge UR, Mirmohammadsadegh A. Adeno-associated virus expresses transgenes in hair follicles and epidermis. Mol. Ther. 2 (3), 188–194 (2000).
63. Donahue BA, McArthur JG, Spratt SK et al. Selective uptake and sustained expression of AAV vectors following subcutaneous delivery. J. Gene Med. 1 (1), 31–42 (1999).
64. Brigham PA, McLoughlin E. Burn incidence and medical care use in the United States: estimates, trends, and data sources. J. Burn Care Rehab. 17 (2), 95–107 (1996).
65. Martin P. Wound healing-aiming for perfect skin regeneration. Science 276 (5309), 75–81 (1997).
66. Branski LK, Pereira CT, Herndon DN, Jeschke MG. Gene therapy in wound healing: present status and future directions. Gene Ther. 14 (1), 1–10 (2007).
67. Deodato B, Arsic N, Zentilin L et al. Recombinant AAV vector encoding human VEGF165 enhances wound healing. Gene Ther. 9 (12), 777–785 (2002).
68. Galeano M, Deodato B, Altavilla D et al. Adeno-associated viral vector-mediated human vascular endothelial growth factor gene transfer stimulates angiogenesis and wound healing in the genetically diabetic mouse. Diabetologia 46 (4), 546–555 (2003).
69. Galeano M, Deodato B, Altavilla D et al. Effect of recombinant adeno-associated virus vector-mediated vascular endothelial growth factor gene transfer on wound healing after burn injury. Crit. Care Med. 31 (4), 1017–1025 (2003).
70. Uutela M, Wirzenius M, Paavonen K et al. PDGF-D induces macrophage recruitment, increased interstitial pressure, and blood vessel maturation during angiogenesis. Blood 104 (10), 3198–3204 (2004).
71. Zacchigna S, Papa G, Antonini A et al. Improved survivial of ischemic cutaneous and musculocutaneous flaps after vascular endothelial growth factor gene transfer using adeno-associated virus vectors. Am. J. Pathol. 167 (4), 981–991 (2005).
72. Rivera VM, Gao G-P, Grant RL et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. Blood 105 (4), 1424–1430 (2005).
73. Hengge UR. Gene therapy progress and prospects: the skin-easily accessible, but still far away. Gene Ther. 13 (22), 1555–1563 (2006).
74. Mavilio F, Pellegrini G, Ferrari S et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat. Med. 12 (12), 1397–1402 (2006).
75. Duan D, Yue Y, Yan Z, Engelhardt JF. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat. Med. 6 (5), 595–598 (2000).
76. Sun L, Li J, Xiao X. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. 6 (5), 599–602 (2000).
77. Watt FM. Epidermal stem cells as targets for gene transfer. Hum. Gene Ther. 11 (16), 2261–2266 (2000).
78. Haug S, Braun-Falco M. Adeno-associated virus vectors are able to restore fatty aldehyde dehydrogenase-deficiency. Implication for gene therapy in Sjögren–Larsson syndrome. Arch. Dermatol. Res. 296 (12), 568–572 (2005).
79. Haug S, Braun-Falco M. Restoration of fatty aldehyde dehydrogenase deficiency in Sjögren–Larsson syndrome. Gene Ther. 13 (13) 1021–1026 (2006).
80. De Semir D, Aran JM. Targeted gene repair: the ups and downs of a promising gene therapy approach. Curr. Gene Ther. 6 (4), 481–504 (2006).
81. Xia H, Mao Q, Eliason SL et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat. Med. 10 (8), 816–820 (2004).
82. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. Exp. Eye Res. 84 (1), 44–52 (2007).
83. Vasileva A, Jessberger R. Precise hit: adeno-associated virus in gene targeting. Nat. Rev. Microbiol. 3 (11), 837–847 (2005).
84. Chamberlain JR, Schwarze U, Wang P-R et al. Gene targeting in stem cells form individuals with osteogenesis imperfecta. Science 303 (5661), 1198–1201 (2004).
85. Cao H, Tsai SY, O’Malley BW, Wang X-J, Roop DR. The epidermis as a bioreactor: Topically regulated cutaneous delivery into the circulation. Hum. Gene Ther. 13 (9), 1075–1080 (2002).
86. Descamps V, Blumenfeld N, Beuzard Y, Perricaudet M. Keratinocytes as a target for gene therapy. Sustained production of erythropoietin in mice by human keratinocytes transduced with an adeno-associated virus vector. Arch. Dermatol. 132 (10), 1207–1211 (1996).
87. Hacker U, Wingenfeld L, Kofler DM et al. Adeno-associated virus serotypes 1 to 5 mediated tumor cell directed gene transfer and improvement of transduction efficiency. J. Gene Med. 7 (11), 1429–1438 (2005).
88. Braun-Falco M, Hallek M. Recombinant adeno-associated virus (rAAV) vector-mediated cotransduction of CD70 and CD80 into human malignant melanoma cells results in an additive T-cell response. Arch. Dermatol. Res. 293 (1–2), 12–17 (2001).
89. Schoensiegel F, Paschen A, Sieger S et al. MIA (melanoma inhibitory activity) promoter mediated tissue-specific suicide gene therapy of malignant melanoma. Cancer Gene Ther. 11 (6), 408–418 (2004).
90. Lin J, Lalani AS, Harding TC et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res. 65 (15), 6901–6909 (2005).